Telomir-1 outperforms FDA-approved DFO in reducing intracellular iron in preclinical study

Telomir Pharmaceuticals, Inc.

Telomir-1 reduced intracellular Fe²⁺ in human keratinocytes in dose- and time-dependent manner at low-micromolar concentrations.
Deferoxamine (DFO) exhibited limited intracellular activity under equivalent conditions.
Telomir-1 formulated with zinc (Telomir-Zn) enables controlled exchange of metal ions – binding excess iron/copper while contributing zinc.
Findings support research into metal-ion balance, oxidative stress, and epigenetic enzyme dynamics in aging and disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.